patient subgroup...
autoimmune disease invasive ventilation no oxygen needed non invasive oxygen
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths 0.92 [0.83, 1.01]< 1 8% 23 studies (23/-) 96.3 % some concern low moderate crucial - deaths (time to event analysis only) 0.93 [0.47, 1.85]< 1 0% 1 study (1/-) 58.2 % low not evaluable high crucial - clinical deterioration 0.68 [0.52, 0.89]< 1 21% 7 studies (7/-) 99.8 % some concern not evaluable moderate important - clinical improvement 1.17 [1.02, 1.36]> 1 36% 11 studies (11/-) 98.5 % some concern low moderate important - clinical improvement (14-day) 1.16 [0.84, 1.60]> 1 0% 2 studies (2/-) 81.0 % some concern not evaluable moderate important - clinical improvement (28-day) 1.23 [0.87, 1.74]> 1 0% 2 studies (2/-) 88.1 % some concern not evaluable moderate important - clinical improvement (7-day) 0.85 [0.56, 1.29]> 1 0% 1 study (1/-) 22.3 % low not evaluable high important - clinical improvement (time to event analysis only) 1.79 [0.63, 5.11]> 1 79% 2 studies (2/-) 86.3 % some concern not evaluable moderate important - death or ventilation 0.81 [0.60, 1.07]< 1 34% 6 studies (6/-) 93.0 % some concern serious moderate important - hospital discharge 1.09 [1.01, 1.18]> 1 7% 4 studies (4/-) 98.8 % some concern not evaluable moderate important - ventilation 0.90 [0.54, 1.51]< 1 0% 5 studies (5/-) 64.9 % some concern not evaluable moderate important - ICU admission 0.43 [0.20, 0.96]< 1 58% 5 studies (5/-) 98.0 % some concern not evaluable moderate non important - time to recovery 1.06 [0.77, 1.46]> 1 0% 1 study (1/-) 63.8 % low not evaluable high non important - safety endpoints 00 serious adverse events 1.21 [0.75, 1.95]< 1 4% 5 studies (5/-) 21.7 % some concern not evaluable moderate important - superinfection 0.79 [0.56, 1.11]< 1 0% 2 studies (2/-) 91.1 % some concern not evaluable moderate important -
LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.